These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
138 related articles for article (PubMed ID: 31628515)
1. Availability of both [ Basu S; Parghane RV; Banerjee S Eur J Nucl Med Mol Imaging; 2020 Apr; 47(4):756-758. PubMed ID: 31628515 [No Abstract] [Full Text] [Related]
2. Safety, Pharmacokinetics, and Dosimetry of a Long-Acting Radiolabeled Somatostatin Analog Zhang J; Wang H; Jacobson O; Cheng Y; Niu G; Li F; Bai C; Zhu Z; Chen X J Nucl Med; 2018 Nov; 59(11):1699-1705. PubMed ID: 29653971 [TBL] [Abstract][Full Text] [Related]
3. Treatment with tandem [90Y]DOTA-TATE and [177Lu]DOTA-TATE of neuroendocrine tumours refractory to conventional therapy. Seregni E; Maccauro M; Chiesa C; Mariani L; Pascali C; Mazzaferro V; De Braud F; Buzzoni R; Milione M; Lorenzoni A; Bogni A; Coliva A; Lo Vullo S; Bombardieri E Eur J Nucl Med Mol Imaging; 2014 Feb; 41(2):223-30. PubMed ID: 24233003 [TBL] [Abstract][Full Text] [Related]
4. Comparison of [(177)Lu-DOTA(0),Tyr(3)]octreotate and [(177)Lu-DOTA(0),Tyr(3)]octreotide: which peptide is preferable for PRRT? Esser JP; Krenning EP; Teunissen JJ; Kooij PP; van Gameren AL; Bakker WH; Kwekkeboom DJ Eur J Nucl Med Mol Imaging; 2006 Nov; 33(11):1346-51. PubMed ID: 16847654 [TBL] [Abstract][Full Text] [Related]
5. Sequential Duo-Peptide Receptor Radionuclide Therapy With Indigenous 90Y-DOTATATE and 177Lu-DOTATATE in Large-Volume Neuroendocrine Tumors: Posttherapy Bremsstrahlung and PET/CT Imaging Following 90Y-DOTATATE Treatment. Parghane RV; Mitra A; Upadhye T; Rakshit S; Banerjee S; Basu S Clin Nucl Med; 2020 Sep; 45(9):714-715. PubMed ID: 32657872 [TBL] [Abstract][Full Text] [Related]
6. Long-term follow-up of renal function after peptide receptor radiation therapy with (90)Y-DOTA(0),Tyr(3)-octreotide and (177)Lu-DOTA(0), Tyr(3)-octreotate. Valkema R; Pauwels SA; Kvols LK; Kwekkeboom DJ; Jamar F; de Jong M; Barone R; Walrand S; Kooij PP; Bakker WH; Lasher J; Krenning EP J Nucl Med; 2005 Jan; 46 Suppl 1():83S-91S. PubMed ID: 15653656 [TBL] [Abstract][Full Text] [Related]
7. Feasibility and utility of re-treatment with (177)Lu-DOTATATE in GEP-NENs relapsed after treatment with (90)Y-DOTATOC. Severi S; Sansovini M; Ianniello A; Bodei L; Nicolini S; Ibrahim T; Di Iorio V; D'Errico V; Caroli P; Monti M; Paganelli G Eur J Nucl Med Mol Imaging; 2015 Dec; 42(13):1955-63. PubMed ID: 26112388 [TBL] [Abstract][Full Text] [Related]
8. Long-term results and tolerability of tandem peptide receptor radionuclide therapy with Kunikowska J; Pawlak D; Bąk MI; Kos-Kudła B; Mikołajczak R; Królicki L Ann Nucl Med; 2017 Jun; 31(5):347-356. PubMed ID: 28316066 [TBL] [Abstract][Full Text] [Related]
9. Clinical Response Profile of Metastatic/Advanced Pulmonary Neuroendocrine Tumors to Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE. Parghane RV; Talole S; Prabhash K; Basu S Clin Nucl Med; 2017 Jun; 42(6):428-435. PubMed ID: 28319500 [TBL] [Abstract][Full Text] [Related]
10. Therapy With Kendi AT; Halfdanarson TR; Packard A; Dundar A; Subramaniam RM AJR Am J Roentgenol; 2019 Aug; 213(2):309-317. PubMed ID: 31039017 [No Abstract] [Full Text] [Related]
11. Overview of Development and Formulation of ¹⁷⁷Lu-DOTA-TATE for PRRT. Breeman WA; Chan HS; de Zanger RM; Konijnenberg MK; de Blois E Curr Radiopharm; 2016; 9(1):8-18. PubMed ID: 25771369 [TBL] [Abstract][Full Text] [Related]
13. Twins in spirit part IV - [ Brogsitter C; Hartmann H; Wunderlich G; Schottelius M; Wester HJ; Kotzerke J Nuklearmedizin; 2017 Feb; 56(1):1-8. PubMed ID: 28138688 [TBL] [Abstract][Full Text] [Related]
14. Thymoma treated with 177Lu DOTATATE induction and maintenance PRRT. Makis W; McCann K; McEwan AJ Clin Nucl Med; 2015 May; 40(5):e278-81. PubMed ID: 25783505 [TBL] [Abstract][Full Text] [Related]
15. High clinical and morphologic response using Kong G; Callahan J; Hofman MS; Pattison DA; Akhurst T; Michael M; Eu P; Hicks RJ Eur J Nucl Med Mol Imaging; 2017 Mar; 44(3):476-489. PubMed ID: 27678267 [TBL] [Abstract][Full Text] [Related]
16. Treatment with tandem [(90)Y]DOTA-TATE and [(177)Lu] DOTA-TATE of neuroendocrine tumors refractory to conventional therapy: preliminary results. Seregni E; Maccauro M; Coliva A; Castellani MR; Bajetta E; Aliberti G; Vellani C; Chiesa C; Martinetti A; Bogni A; Bombardieri E Q J Nucl Med Mol Imaging; 2010 Feb; 54(1):84-91. PubMed ID: 20168290 [TBL] [Abstract][Full Text] [Related]
17. Persistent Hematologic Dysfunction after Peptide Receptor Radionuclide Therapy with Bergsma H; van Lom K; Raaijmakers MHGP; Konijnenberg M; Kam BLBLR; Teunissen JJM; de Herder WW; Krenning EP; Kwekkeboom DJ J Nucl Med; 2018 Mar; 59(3):452-458. PubMed ID: 28775205 [TBL] [Abstract][Full Text] [Related]
18. Safety and Effectiveness of 177Lu-DOTATATE Peptide Receptor Radionuclide Therapy After Regional Hepatic Embolization in Patients With Somatostatin-Expressing Neuroendocrine Tumors. Hamiditabar M; Ali M; Bolek L; Vahdati G; Tworowska I; Delpassand ES Clin Nucl Med; 2017 Nov; 42(11):822-828. PubMed ID: 28832377 [TBL] [Abstract][Full Text] [Related]
19. Orbital Metastases of Neuroendocrine Tumors Treated With 177Lu-DOTATATE PRRT or 131I-MIBG Therapies. Makis W; McCann K; McEwan AJ Clin Nucl Med; 2016 Feb; 41(2):137-41. PubMed ID: 26447382 [TBL] [Abstract][Full Text] [Related]
20. First experience of durable cytoreduction in chronic lymphoid leukemia with Savovic T; Prior JO; Nicod-Lalonde M; Bressoud A; Roux S; Schaefer N; Meyer M Med Oncol; 2019 Mar; 36(5):41. PubMed ID: 30919094 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]